Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 117 points (-0.7%) at 16,295 as of Monday, April 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,136 declining with 146 unchanged. The Drugs industry currently sits down 1.4% versus the S&P 500, which is down 0.8%. Top gainers within the industry include Questcor Pharmaceuticals ( QCOR), up 13.7%, Biogen Idec ( BIIB), up 0.8% and Eli Lilly and Company ( LLY), up 0.6%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 3.6%, Actavis ( ACT), down 2.8%, Allergan ( AGN), down 2.3%, Forest Laboratories ( FRX), down 2.0% and AstraZeneca ( AZN), down 1.0%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $2.65 (0.9%) to $287.99 on average volume. Thus far, 629,926 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $279.04-$292.29 after having opened the day at $280.32 as compared to the previous trading day's close of $285.34. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.2 billion and is part of the health care sector. Shares are up 3.7% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.